CAS: 128-62-1; (-)-Noscapine

上下游产品

CAS号68353-58-2 (S)-7-tert-buto... | CAS号3860-46-6 (-)-β-Narcotine | CAS号186581-53-3 重氮甲烷 | CAS号68353-55-9 7-O-DeMethyl α-... | CAS号70253-41-7 (-)-N-cyano-1(S... | CAS号569-31-3 6,7-二甲氧基-3H-1-异苯并呋喃酮 | CAS号74-89-5 氨基甲烷 | CAS号550-10-7 hydr°Cotarnine | CAS号75-50-3 三甲胺 | CAS号82-54-2 cotarnine | CAS号519-05-1 2-羧基-3,4-二甲氧基苯甲醛 | CAS号518-90-1 3,4-二甲氧酞酸 | CAS号10018-19-6 氯化可替宁

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人：DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

专利号:WO-2025031833-A1
优先权日:2023-08-04
标 题:Recombinant strain and use thereof in production of scoulerine
发明人：CHEN YUN; JIAO XIANG
权利人:CHRYSEA LTD; CHEN YUN
摘要:Disclosed are recombinant yeast strains and a use thereof in the production of a benzylisoquinoline alkaloid. The recombinant yeast strains comprise berberine bridge enzyme. De novo synthesis of scoulerine and a benzylisoquinoline alkaloid is achieved through multiple strategies, and the yield thereof is significantly increased. The recombinant yeast strains provided by the present invention can produce scoulerine and other benzylisoquinoline alkaloids at high efficiency, and has important value in applications.

专利号:US-12416029-B2
优先权日:2016-06-27
标 题 :Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
发明人：FACCHINI PETER JAMES; CHEN XUE; COLBECK JEFFREY C; TUCKER JOSEPH E
权利人:ANTHEIA INC
摘要:Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAsâ€?) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

专利号:US-10793885-B2
优先权日:2013-08-16
标 题 :Compositions and methods for making noscapine and synthesis intermediates thereof
发明人：FACCHINI PETER JAMES; CHEN XUE; DANG THI THU THUY
权利人:WILLOW BIOSCIENCES INC
摘要:Methods for the manufacture of the therapeutic chemical compound noscapine and noscapine synthesis intermediates comprising contacting a noscapine pathway precursor selected from a first canadine derivative, a first papaveroxine derivative and narcotine hemiacetal with at least one of the enzymes selected from the group CYP82Y1, CYP82X1, AT1, CYP82X2, OMT, CXE1 and NOS.